FDA Grants Priority Review for TZIELD (Teplizumab-MZWV) Supplement
The FDA has granted priority review for the supplemental application of TZIELD (Teplizumab-MZWV) by Provention Bio.
Therapeutic Area
Therapeutic area intelligence for Autoimmune with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.